Undifferentiated Castration-Resistant Prostate Cancer Successfully Treated With Carboplatin and Paclitaxel.

Key Points

• The aim is to assess the efficacy of carboplatin and paclitaxel in poorly differentiated castration-resistant prostate cancer (CRPC).
• Examined the effectiveness of carboplatin and paclitaxel treatment.
• Focused on poorly differentiated CRPC cases.
• Highlighted the need for further investigation into platinum-based treatments.
• Treatment showed significant efficacy in the case presented.
• Suggests potential benefits of combining carboplatin with paclitaxel for CRPC.
• Indicates a direction for upcoming research on aggressive prostate cancer therapies.